Academic Background Glioblastoma (GBM) is a highly malignant primary brain tumor. Despite current standard treatments such as surgical resection, radiotherapy, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 14.6 months. Traditional treatments often fail to completely eradicate the tumor and are prone to recur...

Academic Background Glioblastoma (GBM) is one of the most aggressive and heterogeneous central nervous system tumors, with an extremely poor prognosis. Despite the emergence of novel therapies such as anti-angiogenic treatments and immunotherapy in recent years, the survival period of GBM patients remains very limited. GBM cells exhibit unique meta...

Background Introduction Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median survival of approximately 15 months. Despite the use of multimodal treatments including surgery, chemotherapy, and radiotherapy, the overall survival rate of GBM patients has not significantly improved over the past few decades. Recent studies have...

Academic Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with significant treatment challenges and a poor prognosis. Despite advancements in surgery, chemotherapy, and radiotherapy, the 5-year survival rate for GBM patients remains below 4%. The recurrence and therapeutic resistance of GBM are primarily attribut...

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...

Prospective Longitudinal Analysis of Physiologic MRI-Based Tumor Habitat Predicts Short-Term Patient Outcomes in IDH-Wildtype Glioblastoma Academic Background Glioblastoma (GBM) is a highly malignant brain tumor characterized by significant intratumoral heterogeneity, which is evident not only in gene expression and histopathology but also in macro...

Radiation-Induced Cellular Plasticity Primes Glioblastoma for Forskolin-Mediated Differentiation Academic Background Glioblastoma (GBM) is one of the deadliest brain cancers in adults, with a median survival period of only 15 to 18 months for patients. Although surgery combined with chemoradiotherapy can delay disease progression, these treatments ...

Causal Associations Between Sleep Traits, Sleep Disorders, and Glioblastoma: A Two-Sample Bidirectional Mendelian Randomization Study Academic Background Introduction Glioblastoma (GBM) is the most aggressive and common type of malignant brain tumor, accounting for nearly 50% of all primary brain tumors in adults. It primarily originates from astro...

Improving Glioblastoma Treatment with Imaging, Radiotherapy, Drug Delivery, and Therapeutic Systems Academic Background Glioblastoma (GBM) is the most common and aggressive type of brain cancer, with an extremely poor prognosis and a five-year survival rate of less than 10%. Despite decades of extensive research in drug therapy, radiation therapy, ...

The Potential of Oncolytic Cytomegaloviruses Expressing EGFR-Retargeted Fusogenic Glycoprotein Complex and Drug-Controlled IL-12 in Cancer Immunotherapy Background and Objectives In recent years, cancer viroimmunotherapy has emerged as a promising research focus in the field of cancer treatment. This therapy leverages viruses to infect tumor cells,...